SSY Group's SYN045 tablets advance in clinical trials

SSY Group Limited (HKEX:2005) announced that its SYN045 tablets, a Type 1 new chemical drug, has received approval from the National Medical Products Administration of China to add three new specifications (10mg, 25mg, and 50mg) for Phase I clinical trials. The company says this will meet the diversified needs of clinical trials, achieve dose gradients for different age groups, optimize dosing regimens, and enhance the clinical application value of SYN045 tablets. According to a previous announcement dated November 8, 2023, SYN045 is a highly selective PGI2 receptor agonist. Preclinical studies have demonstrated good targeting selectivity, compound activity and safety, and obvious anti-pulmonary hypertension effects in animals, along with low toxicity favourable for long-term oral administration. The company states that the progression of the Phase I clinical trial has put SYN045 on the "fast lane" for this new drug.